Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All colchicine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchColchicineColchicine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

The effect of colchicine on mortality outcome and duration of hospital stay in patients with COVID‐19: A meta‐analysis of randomized trials

Kow et al., Immunity, Inflammation and Disease, doi:10.1002/iid3.562
Dec 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Colchicine for COVID-19
5th treatment shown to reduce risk in September 2020
 
*, now with p = 0.00000031 from 56 studies.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 77 treatments. c19early.org
Meta-analysis of 10 randomized controlled trials with 17,976 COVID-19 patients showing significantly shorter hospitalization with colchicine treatment. Mortality was lower but without statistical significance.
10 meta analyses show significant improvements with colchicine for mortality1-8, oxygen therapy8, hospitalization9, and severity10.
Currently there are 56 colchicine for COVID-19 studies, showing 28% lower mortality [17‑37%], 29% lower ventilation [-15‑56%], 34% lower ICU admission [8‑52%], 19% lower hospitalization [11‑26%], and 9% more cases [-8‑29%].
Kow et al., 30 Dec 2021, peer-reviewed, 6 authors. Contact: long.ming@ubd.edu.bn, pohhui.goh@ubd.edu.bn.
This PaperColchicineAll
The effect of colchicine on mortality outcome and duration of hospital stay in patients with COVID‐19: A meta‐analysis of randomized trials
Chia Siang Kow, Learn‐han Lee, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan, Long Chiau Ming, PAP Hui Poh Goh
Immunity, Inflammation and Disease, doi:10.1002/iid3.562
Background: Overactivation of the NLR family pyrin domain containing 3 (NLRP3) inflammasome can lead to severe illness in patients with coronavirus disease-2019 (COVID-19). The NLRP3 inhibitor, colchicine, therefore, appears to be promising for the treatment of COVID-19. Aims: We aimed to perform a meta-analysis of randomized trials investigating the effect of colchicine in patients with COVID-19. Materials & Methods: We systematically searched electronic databases and clinical trial registries (up to October 17, 2021) for eligible studies. The outcomes of interest were all-cause mortality and duration of hospital stay. Metaanalysis with the random-effects model was used to estimate the pooled odds ratio (OR) of mortality and 95% confidence interval (CI). The pooled standardized mean difference of duration of hospital stay with 95% CI between colchicine users and non-colchicine users was estimated using Cohen's d index. Results: The meta-analyses revealed no significant difference in the odds of mortality (pooled OR = 0.76; 95% CI: 0.53-1.07), but a significant reduction in the duration of hospital stay with the use of colchicine (pooled standardized mean difference = -0.59; 95% CI: -1.06 to -0.13). Discussion and Conclusion: The ability of colchicine to reduce the length of stay in hospitalized patients with COVID-19 is consistent with its potential to prevent clinical deterioration via inhibition of NLRP3 inflammasome. Nevertheless, such beneficial effects of colchicine did not translate into mortality benefits in patients with COVID-19.
CONFLICT OF INTERESTS The authors declare that there are no conflict of interests. AUTHOR CONTRIBUTIONS
References
Bertocchi, Foglietta, Collotta, The hidden role of NLRP3 inflammasome in obesity-related COVID-19 exacerbations: lessons for drug repurposing, Br J Pharmacol
Corona, Pizzocaro, Vena, Diabetes is most important cause for mortality in COVID-19 hospitalized patients: systematic review and meta-analysis, Rev Endocr Metab Disord
Da, Ae, Moral-Escudero, Colchicine in recently hospitalized patients with COVID-19: a randomized controlled trial (COL-COVID), Int J Gen Med
Deftereos, Giannopoulos, Vrachatis, Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial, JAMA Netw Open
Demidowich, Levine, Apps, Colchicine's effects on metabolic and inflammatory molecules in adults with obesity and metabolic syndrome: results from a pilot randomized controlled trial, Int J Obes
Dorward, Yu, Hayward, Colchicine for COVID-19 in adults in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial
Fordham, Kirwan, Cason, Currey, Prolonged reduction in polymorphonuclear adhesion following oral colchicine, Ann Rheum Dis
Gaitán-Duarte, Rincon-Rodriguez, Gonzalez, Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and a combination of them in hospitalized patients with SARS Covid-19
Lambadiari, Kousathana, Raptis, Katogiannis, Kokkinos et al., Pre-existing cytokine and NLRP3 inflammasome activation and increased vascular permeability in diabetes: a possible fatal link with worst COVID-19 infection outcomes?, Front Immunol
Lopes, Bonjorno, Giannini, Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial, RMD Open
Luo, Wan, Liu, Tong, Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range, Stat Methods Med Res
López-Reyes, Martinez-Armenta, Espinosa-Velázquez, NLRP3 inflammasome: the stormy link between obesity and COVID-19, Front Immunol
Mareev, Orlova, Plisyk, Proactive antiinflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study, Kardiologiia
Martinon, Pétrilli, Mayor, Tardivel, Tschopp, Goutassociated uric acid crystals activate the NALP3 inflammasome, Nature
Rodrigues, De Sá, Ishimoto, Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients, J Exp Med
Salehzadeh, Pourfarzi, Ataei, The impact of colchicine on the COVID-19 patients: a clinical trial study
Shi, Luo, Detecting the skewness of data from the sample size and the five-number summary
Sterne, Savović, Page, RoB 2: a revised tool for assessing risk of bias in randomised trials, BMJ
Tardif, Bouabdallaoui, Allier, Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebocontrolled, multicentre trial, The Lancet Respiratory Medicine, doi:10.1016/s2213-2600(21)00222-8
Wan, Wang, Liu, Tong, Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range, BMC Med Res Methodol
{ 'indexed': {'date-parts': [[2024, 1, 18]], 'date-time': '2024-01-18T02:21:22Z', 'timestamp': 1705544482264}, 'reference-count': 22, 'publisher': 'Wiley', 'issue': '2', 'license': [ { 'start': { 'date-parts': [[2021, 12, 30]], 'date-time': '2021-12-30T00:00:00Z', 'timestamp': 1640822400000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by/4.0/'}], 'content-domain': {'domain': ['onlinelibrary.wiley.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2022, 2]]}, 'abstract': '<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Overactivation ' 'of the NLR family pyrin domain containing 3 (NLRP3) inflammasome can lead to severe illness ' 'in patients with coronavirus disease‐2019 (COVID‐19). The NLRP3 inhibitor, colchicine, ' 'therefore, appears to be promising for the treatment of ' 'COVID‐19.</jats:p></jats:sec><jats:sec><jats:title>Aims</jats:title><jats:p>We aimed to ' 'perform a meta‐analysis of randomized trials investigating the effect of colchicine in ' 'patients with COVID‐19.</jats:p></jats:sec><jats:sec><jats:title>Materials &amp; ' 'Methods</jats:title><jats:p>We systematically searched electronic databases and clinical ' 'trial registries (up to October 17, 2021) for eligible studies. The outcomes of interest were ' 'all‐cause mortality and duration of hospital stay. Meta‐analysis with the random‐effects ' 'model was used to estimate the pooled odds ratio (OR) of mortality and 95% confidence ' 'interval (CI). The pooled standardized mean difference of duration of hospital stay with 95% ' "CI between colchicine users and non‐colchicine users was estimated using Cohen's d " 'index.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The meta‐analyses ' 'revealed no significant difference in the odds of mortality (pooled OR = 0.76; 95% CI: ' '0.53–1.07), but a significant reduction in the duration of hospital stay with the use of ' 'colchicine (pooled standardized mean difference = −0.59; 95% CI: −1.06 to ' '−0.13).</jats:p></jats:sec><jats:sec><jats:title>Discussion and ' 'Conclusion</jats:title><jats:p>The ability of colchicine to reduce the length of stay in ' 'hospitalized patients with COVID‐19 is consistent with its potential to prevent clinical ' 'deterioration via inhibition of NLRP3 inflammasome. Nevertheless, such beneficial effects of ' 'colchicine did not translate into mortality benefits in patients with ' 'COVID‐19.</jats:p></jats:sec>', 'DOI': '10.1002/iid3.562', 'type': 'journal-article', 'created': { 'date-parts': [[2021, 12, 31]], 'date-time': '2021-12-31T06:53:53Z', 'timestamp': 1640933633000}, 'page': '255-264', 'update-policy': 'http://dx.doi.org/10.1002/crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 14, 'title': 'The effect of colchicine on mortality outcome and duration of hospital stay in patients with ' 'COVID‐19: A meta‐analysis of randomized trials', 'prefix': '10.1002', 'volume': '10', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-8186-2926', 'authenticated-orcid': False, 'given': 'Chia Siang', 'family': 'Kow', 'sequence': 'first', 'affiliation': [ { 'name': 'School of Postgraduate Studies International Medical University ' 'Kuala Lumpur Malaysia'}, { 'name': 'School of Pharmacy Monash University Malaysia Subang Jaya ' 'Selangor Malaysia'}]}, { 'given': 'Learn‐Han', 'family': 'Lee', 'sequence': 'additional', 'affiliation': [ { 'name': 'Novel Bacteria and Drug Discovery Research Group (NBDD), ' 'Microbiome and Bioresource Research Strength (MBRS), Jeffrey ' 'Cheah School of Medicine and Health Sciences Monash University ' 'Malaysia Subang Jaya Selangor Malaysia'}]}, { 'ORCID': 'http://orcid.org/0000-0001-5390-7026', 'authenticated-orcid': False, 'given': 'Dinesh Sangarran', 'family': 'Ramachandram', 'sequence': 'additional', 'affiliation': [ { 'name': 'School of Pharmacy Monash University Malaysia Subang Jaya ' 'Selangor Malaysia'}]}, { 'ORCID': 'http://orcid.org/0000-0002-4058-2215', 'authenticated-orcid': False, 'given': 'Syed Shahzad', 'family': 'Hasan', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Pharmacy University of Huddersfield Huddersfield ' 'UK'}, { 'name': 'School of Biomedical Sciences and Pharmacy University of ' 'Newcastle Callaghan Australia'}]}, { 'ORCID': 'http://orcid.org/0000-0002-6971-1383', 'authenticated-orcid': False, 'given': 'Long Chiau', 'family': 'Ming', 'sequence': 'additional', 'affiliation': [ { 'name': "PAP Rashidah Sa'adatul Bolkiah Institute of Health Sciences " 'Universiti Brunei Darussalam Gadong Brunei Darussalam'}]}, { 'ORCID': 'http://orcid.org/0000-0002-0480-399X', 'authenticated-orcid': False, 'given': 'Hui Poh', 'family': 'Goh', 'sequence': 'additional', 'affiliation': [ { 'name': "PAP Rashidah Sa'adatul Bolkiah Institute of Health Sciences " 'Universiti Brunei Darussalam Gadong Brunei Darussalam'}]}], 'member': '311', 'published-online': {'date-parts': [[2021, 12, 30]]}, 'reference': [ {'key': 'e_1_2_8_2_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s11154-021-09630-8'}, {'key': 'e_1_2_8_3_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/bph.15229'}, {'key': 'e_1_2_8_4_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1084/jem.20201707'}, {'key': 'e_1_2_8_5_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/nature04516'}, {'key': 'e_1_2_8_6_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/ard.40.6.605'}, {'key': 'e_1_2_8_7_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41366-020-0598-3'}, {'key': 'e_1_2_8_8_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmj.l4898'}, { 'key': 'e_1_2_8_9_1', 'article-title': 'Detecting the skewness of data from the sample size and the five‐number ' 'summary', 'author': 'Shi J', 'year': '2020', 'journal-title': 'arXiv'}, {'key': 'e_1_2_8_10_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1177/0962280216669183'}, {'key': 'e_1_2_8_11_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/1471-2288-14-135'}, { 'key': 'e_1_2_8_12_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jamanetworkopen.2020.13136'}, { 'key': 'e_1_2_8_13_1', 'article-title': 'The impact of colchicine on the COVID‐19 patients: a clinical trial ' 'study', 'author': 'Salehzadeh F', 'year': '2020', 'journal-title': 'Research Square'}, { 'key': 'e_1_2_8_14_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/rmdopen-2020-001455'}, { 'key': 'e_1_2_8_15_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S2213-2600(21)00222-8'}, { 'key': 'e_1_2_8_16_1', 'doi-asserted-by': 'publisher', 'DOI': '10.18087/cardio.2021.2.n1560'}, { 'key': 'e_1_2_8_17_1', 'unstructured': 'Colchicine plus phenolic monoterpenes to treat ' 'COVID‐19.ClinicalTrials.govidentifier: NCT04392141. April 20 2021. ' 'Accessed July 11 ' '2021.https://www.clinicaltrials.gov/ct2/show/NCT04392141'}, { 'key': 'e_1_2_8_18_1', 'article-title': 'Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir ' 'and a combination of them in hospitalized patients with SARS Covid‐19', 'author': 'Gaitán‐Duarte HG', 'year': '2021', 'journal-title': 'medRxiv'}, { 'key': 'e_1_2_8_19_1', 'unstructured': 'The Lancet Respiratory Medicine 2021 Colchicine in patients admitted to ' 'hospital with COVID‐19 (RECOVERY): a randomised controlled open‐label ' 'platform trial'}, {'key': 'e_1_2_8_20_1', 'doi-asserted-by': 'publisher', 'DOI': '10.2147/IJGM.S329810'}, { 'key': 'e_1_2_8_21_1', 'article-title': 'Colchicine for COVID‐19 in adults in the community (PRINCIPLE): a ' 'randomised, controlled, adaptive platform trial', 'author': 'Dorward J', 'year': '2021', 'journal-title': 'medRxiv'}, {'key': 'e_1_2_8_22_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fimmu.2020.570251'}, {'key': 'e_1_2_8_23_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fimmu.2020.557235'}], 'container-title': 'Immunity, Inflammation and Disease', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1002/iid3.562', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://onlinelibrary.wiley.com/doi/full-xml/10.1002/iid3.562', 'content-type': 'application/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1002/iid3.562', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 8, 28]], 'date-time': '2023-08-28T08:40:36Z', 'timestamp': 1693212036000}, 'score': 1, 'resource': {'primary': {'URL': 'https://onlinelibrary.wiley.com/doi/10.1002/iid3.562'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 12, 30]]}, 'references-count': 22, 'journal-issue': {'issue': '2', 'published-print': {'date-parts': [[2022, 2]]}}, 'alternative-id': ['10.1002/iid3.562'], 'URL': 'http://dx.doi.org/10.1002/iid3.562', 'relation': {}, 'ISSN': ['2050-4527', '2050-4527'], 'subject': ['Immunology', 'Immunology and Allergy'], 'container-title-short': 'Immunity Inflam &amp;amp; Disease', 'published': {'date-parts': [[2021, 12, 30]]}, 'assertion': [ { 'value': '2021-08-11', 'order': 0, 'name': 'received', 'label': 'Received', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2021-10-29', 'order': 1, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2021-12-30', 'order': 2, 'name': 'published', 'label': 'Published', 'group': {'name': 'publication_history', 'label': 'Publication History'}}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit